Chemo-Induced Ovarian Failure in Young Women with Breast Cancer
the Cancer Therapy Advisor take:
Ovarian toxicity may derive from acute vascular insult caused by chemotherapy in patients with breast cancer, according to an article published online in the journal The Oncologist.
Participants in this study included 20 patients (median age of 34 ± 5.24 years) diagnosed with localized breast cancer. Transvaginal ultrasound was used to evaluate the patients prior to initiation of chemotherapy, immediately following treatment completion, and at 6 and 12 months post-treatment.
Using resistance index and pulsatility index, the authors concluded that ovarian blood flow was significantly reduced immediately following chemotherapy treatment (P=0.01). Patients younger than 35 years significantly regained ovarian vasculature after 6 and 12 months post-treatment, compared with patients older than 35 years (P<0.05).
Furthermore, all patients experienced a significant drop in anti-Müllerian hormone (AMH) levels following treatment (P=0.04). At 12 months, 50% of patients resumed menses.
Results indicated that chemotherapy-induced ovarian toxicity may result from acute vascular insult caused by treatment.
The authors noted that ovarian vasculature impairment was diminished in patients who underwent a trastuzumab-based treatment, although results were not statistically significant (P=0.068).
The study suggests future research work to further understand and characterize patterns of chemotherapy-induced vascular toxicity for specific organs.
Ovarian toxicity may derive from acute vascular insult caused by chemotherapy in patients with breast cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma